BioSpace News Archive

Qualigen Therapeutics, Inc., has completed its previously announced merger transaction with Qualigen, Inc., a company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as the worldwide sales of its flagship FastPack® rapid diagnostic platform.

Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced its financial results for the first quarter, ended March 31, 2020.

HUB patient-derived organoids (PDO) added to CrownBio’s unique platform designed to disrupt traditional drug discovery workflows

Neos Therapeutics, Inc. announced that Jerry McLaughlin, President and Chief Executive Officer, will present a company overview at the upcoming Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, 2020, at 9:00 a.m. ET.

RAPT Therapeutics, Inc. announced that Brian Wong, M.D., Ph.D., President and CEO, will present a corporate update and company overview at the Jefferies 2020 Healthcare Conference on Tuesday, June 2nd at 9:30 a.m. Eastern Time.

Strategic investment at a premium enhances Company’s ongoing development activities of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab to treat wet AMD, toward FDA approval

Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 2-4, 2020.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP, a closely held biotechnology company, today announced that the companies have entered into a collaboration agreement to develop EIDD-2801, an orally available antiviral candidate currently in early clinical develop

May 26, 2020 10:49 UTC New Collaboration to Leverage Complementary Expertise and Capabilities with rVSV Technology to Advance Novel Vaccine Candidate KENILWORTH, N.J. & NEW YORK--( BUSINESS WIRE )-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, today announced a new collaboration to develop an investigational vaccine against SARS

Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, provided an update on the progress it is making with its partner, Teledyne Scientific & Imaging, in further validating the power of Resonant’s Infinite Synthesized Networks (ISN ® ) software platform by developing wide bandwidth, high frequency XBAR ® filters with its fou